Ocuphire Pharma, Inc. (OCUP)

Ocuphire Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	51	68	73	65	7	8
Market Cap Growth	-36.51%	-7.23%	13.82%	787.14%	-5.24%	-78.00%
Enterprise Value	4	18	31	40	-9	12
PE Ratio	-	-6.82	4.11	-1.14	-0.29	-1.24
PS Ratio	2.71	3.58	1.84	109.56	-	-
PB Ratio	1.12	1.37	1.59	2.90	-0.54	-1.01
P/FCF Ratio	-15.67	-61.28	5.13	-3.33	-1.07	-2.12
P/OCF Ratio	-15.67	-61.28	5.13	-3.33	-1.07	-2.14
EV/Sales Ratio	0.23	0.93	0.77	68.45	-	-
EV/EBITDA Ratio	-0.24	-1.77	1.69	-0.71	0.51	-2.48
EV/EBIT Ratio	-0.24	-1.77	1.69	-0.71	0.51	-2.48
EV/FCF Ratio	-0.85	-15.85	2.15	-2.08	1.34	-3.26
Debt / Equity Ratio	-	-	-	0.02	-	-0.75
Debt / EBITDA Ratio	-	-	-	-0.01	-	-1.19
Debt / FCF Ratio	-	-	-	-0.03	-	-1.57
Quick Ratio	8.69	13.07	17.27	6.42	5.15	0.16
Current Ratio	8.96	13.35	17.79	6.76	5.55	0.19
Asset Turnover	0.37	0.39	1.56	0.03	0	0
Interest Coverage	-	-	2023.56	-28345.50	-2.60	-3.38
Return on Equity (ROE)	-24.60%	-22.30%	79.50%	-301.70%	-1132.50%	-73.10%
Return on Assets (ROA)	-22.20%	-20.30%	70.20%	-261.70%	-203.80%	-45.80%
Return on Capital (ROIC)	-26.36%	-21.17%	38.73%	-99.76%	148.27%	221.50%
Earnings Yield	-21.91%	-14.66%	24.35%	-87.85%	-338.47%	-80.36%
FCF Yield	-6.17%	-1.63%	19.49%	-30.02%	-93.44%	-47.13%
Buyback Yield / Dilution	-17.10%	-4.82%	-38.68%	-218.65%	-63.84%	-315.53%
Total Shareholder Return	-17.10%	-4.82%	-38.68%	-218.65%	-63.84%	-315.53%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).